Granell, MiquelCalvo Gonzalo, XavierGarcia-Guiñón, AntoniEscoda, LourdesAbella Monreal, EugeniaMartínez, Clara M.Teixidó, MontserratGimenez, Mª TeresaSenín Magan, Maria AliciaSanz, PatriciaCampoy, DesiréeVicent, AnaArenillas Rocha, LeonorRosiñol, LauraSierra, JorgeBlade, JoanFernández de Larrea, CarlosGEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya)2018-01-172018-01-172017Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM. Et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017 Jun;102(6):1099-1104. DOI: 10.3324/haematol.2016.1583030390-6078http://hdl.handle.net/10230/33650The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×109/L vs 214×109/L, P<0.0001) and higher bone marrow plasma cells (median 53% vs 36%, P=0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.application/pdfengMaterial published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.LeucèmiaCàncer -- Aspectes genèticsinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3324/haematol.2016.158303info:eu-repo/semantics/openAccess